Janus kinase 3 (JAK3) and TEC family kinases (JAK3/TEC)

Janus kinase 3 (JAK3) and the TEC family of kinases (comprising TEC, BTK, ITK, RLK, and BMX) represent a specialized signaling network primarily expressed in hematopoietic cells [2, 5]. JAK3 is a non-receptor tyrosine kinase that associates with the common gamma chain (γc) of cytokine receptors to mediate signaling for interleukins essential for lymphocyte development and function [1, 13]. The TEC family kinases are critical mediators of signaling downstream of antigen receptors, such as the T-cell receptor (TCR) and B-cell receptor (BCR), where they regulate lymphocyte activation and the release of inflammatory mediators [4, 8]. Dual inhibition of these pathways, exemplified by the first-in-class drug ritlecitinib, provides a potent means of modulating both cytokine-driven and antigen-driven immune responses [2, 11]. This combined targeting is particularly effective in treating autoimmune conditions like alopecia areata and vitiligo, where it suppresses the activity of cytotoxic T-cells and disrupts inflammatory feedback loops [4, 7]. Covalent inhibitors of this target profile typically exploit a conserved cysteine residue in the ATP-binding pocket to achieve high selectivity for JAK3 and TEC family members over other JAK isoforms, potentially improving the safety profile relative to pan-JAK inhibitors [2, 6].

Other names

JAK3 and TEC familyJanus kinase 3 and TEC familyJAK3/TEC kinasesJanus kinase 3 and Tyrosine kinase expressed in hepatocellular carcinoma family

Irreversible covalent inhibition of the ATP-binding site of Janus kinase 3 and TEC family kinases, blocking common gamma chain cytokine signaling and antigen receptor-mediated lymphocyte activation [1, 2, 4].